SCHEMBL30007870

SCHEMBL30007870

CONc1cc(Cl)nc2c1cnn2[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H]1OC(C)=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.54
THRB P10828 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
HIF1A Q16665 1/20 0.54
ALDH1A1 P00352 2/20 0.47
TP53 P04637 1/20 0.47
MAPT P10636 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
NT5E P21589 3/20 0.43
XDH P47989 1/20 0.39
PRKAB2 O43741 1/20 0.39
PRKAG1 P54619 1/20 0.39
PRKAA2 P54646 1/20 0.39
PRKAA1 Q13131 1/20 0.39
PRKAG3 Q9UGI9 1/20 0.39
PRKAG2 Q9UGJ0 1/20 0.39
PRKAB1 Q9Y478 1/20 0.39
PRKCA P17252 1/20 0.39
AKT1 P31749 1/20 0.39
PTK2 Q05397 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24672044 0.91 LMNA (0.52) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL27270722 0.88 NT5E (0.58) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL30866966 0.88 NT5E (0.58) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL19370333 0.88 LMNA (0.58) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL24452645 0.88 LMNA (0.58) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL24452646 0.88 LMNA (0.58) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL24452562 0.81 LMNA (0.64) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL22215103 0.81 LMNA (0.64) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL22628718 0.81 LMNA (0.64) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL19370225 0.81 LMNA (0.64) LMNATHRBSMN1; SMN2HIF1AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368204-A1 SMALL MOLECULAR CD73 ANTAGONIST AND USE THEREOF XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) 2024-11-07 US disclosed
EP-4353732-A1 SMALL MOLECULAR CD73 ANTAGONIST AND USE THEREOF Xizang Haisco Pharmaceutical Co., Ltd. (CN) 2024-04-17 EP disclosed
CN-117642411-A Small molecule CD73 antagonists and uses thereof 西藏海思科制药有限公司 2024-03-01 CN disclosed
WO-2022237747-A1 SMALL MOLECULAR CD73 ANTAGONIST AND USE THEREOF 四川海思科制药有限公司 2022-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368204-A1 SMALL MOLECULAR CD73 ANTAGONIST AND USE THEREOF ENTPD5, ENTPD1, ENTPD2 LMNA 2664/4885THRB 2381/4885SMN1; SMN2 2925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.